Apollo Hospitals and Max Healthcare Rally After Macquarie Turns Positive on Hospital Stocks

Mumbai, November 21, 2026: Shares of Apollo Hospitals Enterprise and Max Healthcare Institute surged during trading on Friday, November 20, after global brokerage Macquarie upgraded both companies from Underperform to Outperform, citing improving earnings expectations, more attractive valuations and stronger utilisation of newly added hospital capacity.

Apollo Hospitals gained more than 5% during the session and reached a fresh record high, while Max Healthcare advanced over 4% to a three-month high.

Macquarie raised its target price for Apollo Hospitals to ₹10,500 from ₹6,230 and increased its target for Max Healthcare to ₹1,450 from ₹825.

The brokerage's decision represents a two-notch upgrade for both hospital operators, reflecting a significant change in its assessment of their earnings prospects.

Macquarie believes that earnings expectations have stabilised after earlier downward revisions and that the financial impact of hospital expansion is increasingly reflected in existing valuations.

The brokerage also identified Max Healthcare as offering a more favourable risk-reward profile, supported by its capital allocation strategy and expected earnings growth.

The upgrades brought renewed attention to India's hospital industry, where companies are expanding bed capacity to meet demand for specialised healthcare services.

Key Highlights of Macquarie's Hospital Stock Upgrades

Parameter

Apollo Hospitals

Max Healthcare

Company

Apollo Hospitals Enterprise

Max Healthcare Institute

Previous rating

Underperform

Underperform

New rating

Outperform

Outperform

Previous target price

₹6,230

₹825

Revised target price

₹10,500

₹1,450

Intraday share-price gain

More than 5%

More than 4%

Reported intraday high

₹9,205

₹1,090

Key investment driver

Earnings recovery and hospital capacity utilisation

Expansion execution and EBITDA growth

Macquarie's relative preference

Positive

Preferred risk-reward

The target prices represent Macquarie's research estimates, not guaranteed future trading levels.

Apollo Hospitals Shares Hit Record High After Brokerage Upgrade

Apollo Hospitals emerged as one of the strongest performers in India's healthcare sector during the November 20 trading session.

The stock climbed more than 5% to reach an intraday high of approximately ₹9,205.

The rally followed Macquarie's decision to raise its rating directly from Underperform to Outperform.

The brokerage increased its target price by ₹4,270 per share, representing an upward revision of approximately 68.5%.

The revised target reflects expectations that Apollo Hospitals can benefit from improving hospital occupancy, growth in specialised medical procedures and stronger utilisation of its healthcare infrastructure.

The company has also been expanding its hospital network and developing its healthcare services businesses.

Macquarie believes that the initial profitability pressure associated with capacity expansion is already substantially reflected in market expectations.

The brokerage expects operational improvements to support earnings growth as newly commissioned facilities mature.

Max Healthcare Shares Jump Over 4% to Three-Month High

Max Healthcare also recorded substantial gains following the brokerage upgrade.

Its shares advanced more than 4% to an intraday high of approximately ₹1,090.

Macquarie raised the company's target price from ₹825 to ₹1,450, an increase of approximately 75.8%.

The brokerage considers Max Healthcare particularly attractive because of its focused capital allocation and expected improvement in operating performance.

Max Healthcare has been expanding its hospital capacity, which can temporarily affect profitability while new facilities build patient volumes.

However, Macquarie believes the financial impact of these expansion costs has largely been incorporated into market valuations.

The brokerage expects improving utilisation and operating efficiency to support future earnings.

Macquarie's Revised Target Prices Signal Stronger Expectations

Macquarie target price revisions — November 20, 2026

Chart

■ Previous target

■ Revised target

Brokerage targets reported November 20, 2026

 
Target prices are brokerage estimates and may change with earnings forecasts, valuations and market conditions.

The revised targets demonstrate the extent of Macquarie's change in outlook.

Apollo Hospitals' target increased by approximately 68.5%, while Max Healthcare's target rose approximately 75.8%.

The revisions reflect both changes in earnings expectations and the valuation multiples the brokerage considers appropriate.

However, target price increases do not necessarily translate into equivalent share-price gains.

Actual market performance depends on company results, investor sentiment, broader market conditions and future developments.

Why Macquarie Upgraded Both Hospital Companies

Macquarie's revised outlook is based on several developments affecting India's hospital sector.

The brokerage believes consensus earnings expectations have reached a more sustainable level following earlier reductions.

It also considers that valuations have become more reasonable compared with previous periods.

A third factor is the improving utilisation of newly commissioned hospital capacity.

Hospital expansion typically requires substantial investment before new facilities reach mature operating levels.

During the initial period, staffing, equipment, maintenance and other operating costs can weigh on profitability.

As patient volumes increase, fixed costs are spread across a larger revenue base.

This can improve operating margins and profitability.

Macquarie believes the current expansion cycle is progressing sufficiently well to support a more favourable earnings outlook.

New Hospital Capacity Expected to Support Revenue Growth

Hospital capacity expansion is an important component of growth strategies for major Indian healthcare operators.

Companies add beds to increase patient capacity, expand specialised treatment services and strengthen their presence in important healthcare markets.

However, newly commissioned facilities generally require time to achieve optimal occupancy.

During this period, operating costs may rise faster than revenue.

The resulting pressure on margins can influence investor expectations.

Macquarie believes that recently commissioned facilities are recording healthy utilisation trends.

This could shorten the period during which new hospitals dilute group profitability.

Mature hospitals also provide opportunities for improved revenue generation through higher occupancy, treatment complexity and patient mix.

These developments are expected to support earnings as capacity additions become more productive.

Max Healthcare Expected to Deliver 20% Revenue CAGR Through FY29

Macquarie's outlook for Max Healthcare includes substantial revenue and earnings growth expectations.

The brokerage forecasts a compound annual growth rate of approximately 20% in revenue between FY26 and FY29.

It also expects EBITDA to increase at a compound annual rate of approximately 22% over the same period.

Macquarie's Max Healthcare growth projections, FY26–FY29

Revenue CAGR

20%

EBITDA CAGR

22%

Brokerage forecasts, not reported historical growth rates.

The projected EBITDA growth rate is slightly higher than the revenue growth rate.

This suggests expectations for improved operating leverage and profitability.

Macquarie also increased its FY27 consolidated earnings forecast for Max Healthcare by approximately 2%, while maintaining its FY28 estimate.

The brokerage believes that earlier downward revisions have made market expectations more realistic.

However, the forecasts remain dependent on the successful commissioning and utilisation of new hospital capacity.

Max Healthcare's Valuation Becomes More Attractive

Macquarie has also revised its valuation assumptions for Max Healthcare.

The brokerage increased its FY29 estimated pro forma enterprise value-to-EBITDA multiple from 22 times to 30 times.

According to the brokerage's assessment, Max Healthcare trades at approximately 29 times its one-year forward EV/EBITDA.

This compares with a five-year average of approximately 31 times.

EV/EBITDA is a valuation metric that compares a company's enterprise value with its earnings before interest, tax, depreciation and amortisation.

It is frequently used to assess capital-intensive businesses, including hospitals.

A lower multiple relative to historical levels can indicate a more moderate valuation.

However, it does not automatically establish that a stock is undervalued.

The appropriate multiple depends on earnings growth, financial risk, capital expenditure requirements and industry conditions.

Apollo Hospitals Reports Strong September-Quarter Earnings

Apollo Hospitals' recent financial performance provides additional context for the brokerage upgrade.

The company reported strong growth in revenue and profitability during the September quarter of FY27.

Its consolidated revenue increased approximately 23% year over year to ₹7,615 crore.

Reported net profit rose approximately 33.6% to ₹660 crore, while EBITDA increased 28.8% to ₹1,191 crore.

The EBITDA margin improved to approximately 15.6%, compared with 14.9% in the corresponding quarter of the previous year.

Financial Indicator

Q2 FY27

Year-on-Year Change

Consolidated revenue

₹7,615 crore

+23%

Reported net profit

₹660 crore

+33.6%

EBITDA

₹1,191 crore

+28.8%

EBITDA margin

15.6%

Up from 14.9%

Hospital occupancy

73%

Up from 69%

Inpatient volume

—

+14%

The improvement in hospital occupancy and patient volumes indicates stronger utilisation of existing infrastructure.

Higher operating efficiency can help hospitals absorb fixed costs and improve margins.

The company's results also demonstrate continued demand for specialised healthcare services.

Hospital Occupancy Becomes a Critical Earnings Indicator

Occupancy is one of the most important operating metrics for hospital companies.

It measures the proportion of available beds occupied by patients during a specified period.

Higher occupancy generally supports revenue generation because hospital infrastructure and staffing costs are spread across more patients.

However, profitability also depends on treatment complexity, pricing, patient mix and operating expenses.

Apollo Hospitals reported occupancy of approximately 73% during the September quarter, compared with 69% a year earlier.

The improvement reflects stronger utilisation of hospital capacity.

Inpatient volumes also increased approximately 14%.

These developments support the view that established hospitals can generate additional earnings through operational improvements.

For newer facilities, the pace of occupancy growth will remain an important determinant of profitability.

Average Revenue per Occupied Bed Supports Profitability

Another important metric is average revenue per occupied bed, commonly referred to as ARPOB.

The measure indicates the average revenue generated from an occupied hospital bed over a specified period.

ARPOB can increase when hospitals provide more complex treatments, improve their service mix or adjust pricing.

Apollo Hospitals reported an approximately 8% increase in ARPOB during the September quarter.

The figure reached approximately ₹1,86,880.

Growth in ARPOB can support revenue even when physical bed capacity remains unchanged.

However, higher revenue per bed must be considered alongside treatment costs and affordability.

The sustainability of ARPOB growth depends on patient demand, clinical services, pricing arrangements and regulatory conditions.

Oncology Drug Pricing Regulations Remain a Sector Risk

Despite the positive brokerage upgrades, India's hospital industry faces regulatory risks.

One concern involves government measures affecting the pricing of oncology medicines.

The National Pharmaceutical Pricing Authority has revised prices for 137 non-scheduled anti-cancer drugs.

The regulatory action is intended to improve affordability for patients.

However, lower medicine prices can affect revenue and margins for hospitals that earn income from pharmaceutical sales.

Analysts have previously estimated that the pricing changes could create a meaningful EBITDA impact for certain hospital operators.

The extent of the effect will depend on individual companies' treatment mix, drug sales exposure and ability to adjust other service prices.

Any additional extension of price controls could also influence profitability.

Macquarie's positive outlook does not eliminate these regulatory uncertainties.

Expansion Costs Could Still Affect Near-Term Margins

Hospital expansion requires substantial capital investment.

New facilities need medical equipment, specialised staff, technology systems and supporting infrastructure.

These expenses may begin before patient volumes reach expected levels.

As a result, newly commissioned hospitals can initially report lower margins than mature facilities.

Macquarie believes much of this pressure has already been reflected in market expectations.

However, delays in capacity utilisation could still affect future earnings.

Higher operating costs, slower patient acquisition or changes in treatment demand could also reduce expected profitability.

The pace at which new hospitals achieve sustainable occupancy will therefore remain important.

Apollo Hospitals' Diversified Business Model Provides Multiple Growth Drivers

Apollo Hospitals operates across several healthcare segments.

Its businesses include hospitals, pharmacies and digital healthcare services.

This diversified structure provides exposure to different areas of healthcare demand.

Hospital operations benefit from demand for inpatient procedures and specialised treatment.

Pharmacy operations provide access to recurring consumer healthcare purchases.

Digital healthcare services offer opportunities in online consultations, medicine delivery and related activities.

However, the segments have different profitability characteristics and capital requirements.

Investors will monitor whether growth across these businesses translates into stronger consolidated earnings.

Macquarie has identified elevated operating costs in Apollo's HealthCo business as one potential constraint on margin expansion.

Why Macquarie Prefers Max Healthcare Over Apollo Hospitals

Although Macquarie upgraded both stocks, it expressed a relative preference for Max Healthcare.

The brokerage believes Max offers a more favourable balance between potential returns and investment risks.

Its assessment reflects expectations for disciplined capital allocation, strong EBITDA growth and improving utilisation of new hospital capacity.

The company's projected 20% revenue CAGR and 22% EBITDA CAGR between FY26 and FY29 are central to that view.

Apollo Hospitals also benefits from improving operating performance and a diversified healthcare business.

However, Macquarie's target price suggests a smaller percentage gap relative to the share price observed during the November 20 session.

The distinction reflects the brokerage's valuation assumptions and expectations rather than a guarantee that Max Healthcare will outperform Apollo Hospitals.

Healthcare Stocks Gain Attention Amid Broader Market Volatility

The rally in hospital shares occurred during a period of uncertainty in global equity markets.

Technology-related stocks have experienced selling pressure as investors reassess artificial intelligence valuations and infrastructure spending.

Indian healthcare companies operate in a different demand environment, with revenue driven primarily by medical treatment and healthcare services.

This can make the sector attractive to investors seeking exposure to domestic economic activity.

However, healthcare stocks are not insulated from market volatility.

Their valuations can be affected by interest rates, foreign investment flows, regulatory developments and changes in earnings expectations.

The November 20 rally primarily reflected a company-specific and sector-specific brokerage development.

What Investors Will Monitor in the Coming Quarters

Future earnings reports will be important in determining whether the improved outlook is sustained.

For Max Healthcare, attention will focus on the utilisation of new hospitals, revenue growth and EBITDA margins.

Investors will also assess whether the company can achieve the earnings growth projected by Macquarie.

For Apollo Hospitals, important indicators will include hospital occupancy, inpatient volumes, ARPOB and profitability across its diversified businesses.

The effect of oncology drug pricing regulations will remain relevant for the broader sector.

Capital expenditure and financing requirements will also influence financial performance.

The companies' ability to translate capacity expansion into stronger earnings will be central to future valuations.

Conclusion

Apollo Hospitals and Max Healthcare shares rallied sharply on November 20, 2026, after Macquarie upgraded both hospital operators from Underperform to Outperform.

Apollo Hospitals gained more than 5% during the session and reached a fresh record high, while Max Healthcare advanced over 4%.

The brokerage raised its target price for Apollo Hospitals to ₹10,500 and Max Healthcare to ₹1,450.

Macquarie's improved outlook reflects stabilising earnings expectations, more reasonable valuations and stronger utilisation of newly commissioned hospital capacity.

The brokerage identified Max Healthcare as offering a more favourable risk-reward profile, supported by projected revenue growth of 20% and EBITDA growth of 22% annually between FY26 and FY29.

Apollo Hospitals' recent quarterly results also demonstrated strong revenue growth, improving occupancy and higher operating profitability.

However, regulatory pricing measures, hospital expansion costs and execution risks remain important considerations.

The sustainability of the rally will depend on whether both companies deliver the earnings improvements anticipated by the brokerage.